symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
KNTE,1.24,0.267322,179534,58397676,0,1.18-10.56,-0.06,Kinnate Biopharma Inc.,USD,0001797768,US49705R1059,49705R105,NASDAQ Global Select,NASDAQ,Biotechnology,https://www.kinnate.com,"Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.",Mr. Nima  Farzan M.B.A.,Healthcare,US,84,858 299 4699,103 Montgomery Street,San Francisco,CA,94129,,0,https://financialmodelingprep.com/image-stock/KNTE.png,2020-12-03,False,False,True,False,False
